About Biocon Our Business Research & Development Biocon's Technology Investors Media Careers CSR
Formulation & Fill-Finish
  Microbial Fermentation
  Human Insulin & Biosimilars
  Mammalian Cell Culture
  Formulation & Fill-Finish
  Chemical Synthesis
  Formulation & Fill-Finish

The launch of human insulin in 2004 represented Biocon’s foray into the aseptic formulations space. In order to facilitate the complex formulation requirements for insulin with different pharmacokinetic profiles, and also to support the extensive pipeline of protein, peptide and antibody products, Biocon commissioned its first aseptic formulation and fill-finish facility. This facility is equipped to deliver liquid and lyophilized vials, cartridges for injection devices (pens) and pre-filled syringes. The multi-product facility can also cater to similar requirements from clients and partners and is designed to the highest of international standards, especially since protein and antibody products, unlike small molecules, cannot be terminally sterilized. This facility has been approved by several National Regulatory Agencies around the world and fulfills the global demand for Biocon’s sterile injectable products.


Recommended sites Biocon on  
About Us

Investor Relations
Media Relations
Site Map
Contact Us
Our Growth Accelerators
Fact Sheet
Branded Formulations
Research Services
Active Discovery Program

Karnataka Vision Group on BT
Syngene International
Biocon Academy

    Linked In   
  Report adverse event/side effects and product complaints    
  * Disclaimer            © 2018, Biocon. All Rights Reserved